Cost-effectiveness of Osimertinib vs Docetaxel-Bevacizumab in Third-Line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.
Sign Up to like & getrecommendations! Published in 2020 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2020.08.018
Abstract: PURPOSE This study aimed to evaluate the cost-effectiveness of osimertinib vs docetaxel and bevacizumab in third-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China from the perspective of the health… read more here.
Keywords: per qaly; egfr t790m; docetaxel bevacizumab; model ... See more keywords
Docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer: a meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "European review for medical and pharmacological sciences"
DOI: 10.26355/eurrev_202109_26643
Abstract: OBJECTIVE Although bevacizumab and trastuzumab have been widely added to the standard regimen for metastatic breast cancer, the clinical outcomes remain controversial. The purpose of this study was to conduct meta-analysis to verify the clinical… read more here.
Keywords: metastatic breast; trastuzumab; docetaxel bevacizumab; breast cancer ... See more keywords